Detailed results from pivotal TALAPRO-3 study presented at ASCO 2026 and published in The New England Journal of Medicine ...
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent ...
Cribriform-positive morphology was associated with a 3.6-fold higher risk for metastasis in patients with prostate cancer, and radiotherapy with neoadjuvant androgen deprivation therapy (ADT) was ...
SurvivorNet on MSN
ASCO 2026: A major prostate cancer trial shows drug can keep high-risk disease from returning for longer
Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...
Impact of homologous recombination repair alterations (HRRalt) on survival outcomes of patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Effects of emerin dysregulation on the ...
Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto ® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of ...
SPOP mutations in veterans with metastatic castration-resistant prostate cancer (mCRPC) and the association with race and response to an androgen receptor pathway inhibitor (ARPI). This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results